Not for distribution to U.S. news wire services or dissemination in the United States

WINNIPEG, Manitoba, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSXV:KNE) ("Kane Biotech", "Kane" or the "Company") today announces its intention to undertake a non-brokered private placement offering (the "Offering") of up to 16 million common shares ("Shares") at a price of $0.05 per Share for gross proceeds of up to $800,000.

The net proceeds of the Offering will be used for working capital and general corporate purposes. Certain insiders of Kane Biotech may participate in the Offering. Closing of the Offering is expected to take place on or about December 17, 2025.

All Shares issued in connection with the Offering are subject to a hold period of four-months and one day from the date of issuance.

The Offering is subject to receipt of all necessary approvals, including the approval of the TSX Venture Exchange.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. These ...